Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Mar 27, 2023 · Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic …
FDA approves dostarlimab-gxly with chemotherapy for endometrial cancer
On July 31, 2023, the Food and Drug Administration approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, …
Primary Advanced or Recurrent Endometrial Cancer Treatment
Discover JEMPERLI (dostarlimab-gxly) + CP, an IO-based treatment for primary advanced or recurrent endometrial cancer. See full Indication, Safety, & PI.
Results for JEMPERLI | JEMPERLI (dostarlimab-gxly)
JEMPERLI + carboplatin and paclitaxel (CP): The FIRST AND ONLY FDA-approved immunotherapy combination proven to help patients with newly-diagnosed advanced or …
EC Treatment Option for Certain Patients | JEMPERLI (dostarlimab …
JEMPERLI is an immunotherapy that may help you fight certain types of advanced or returned endometrial cancer.
OS data set up wider Jemperli use in endometrial cancer
Jan 23, 2025 · GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in the …
FDA Expands Approval for Jemperli in Endometrial Cancer
Aug 2, 2024 · The US Food and Drug Administration (FDA) has approved dostarlimab (Jemperli) in combination with carboplatin and paclitaxel, followed by dostarlimab as a single agent, for …
Jemperli New Standard of Care for Advanced Uterine/Endometrial Cancer
Apr 27, 2020 · Jemperli (dostarlimab) immunotherapy advances treatment of endometrial cancer, especially those with MSI-H or dMMR defects.
Jemperli vs Keytruda for endometrial cancer: What’s the …
Sep 4, 2023 · Both Jemperli (dostarlimab) and Keytruda (pembrolizumab) are prescribed as second-line treatments for advanced endometrial cancer that is microsatellite instability-high …
Jemperli: Uses, Dosage, Side Effects, Warnings - Drugs.com
Aug 7, 2024 · Jemperli (dostarlimab-gxly) is a cancer immunotherapy used to treat types of endometrial cancer and solid tumors. Includes Jemperli side effects, indications, and doses.